Symbiotec Pharmalab Statistics
Total Valuation
NSE:SYMBIOTEC has a market cap or net worth of INR 100.63 billion. The enterprise value is 103.77 billion.
Important Dates
The last earnings date was Thursday, November 5, 2026.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:SYMBIOTEC has 64.26 million shares outstanding. The number of shares has increased by 9.97% in one year.
| Current Share Class | 64.26M |
| Shares Outstanding | 64.26M |
| Shares Change (YoY) | +9.97% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | 12.93% |
| Owned by Institutions (%) | 42.79% |
| Float | 25.98M |
Valuation Ratios
The trailing PE ratio is 75.90 and the forward PE ratio is 61.23. NSE:SYMBIOTEC's PEG ratio is 1.66.
| PE Ratio | 75.90 |
| Forward PE | 61.23 |
| PS Ratio | 10.39 |
| PB Ratio | 7.39 |
| P/TBV Ratio | 7.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 106.08 |
| PEG Ratio | 1.66 |
Financial Ratio History Enterprise Valuation
| EV / Earnings | 82.01 |
| EV / Sales | 10.71 |
| EV / EBITDA | 38.59 |
| EV / EBIT | 53.76 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.36 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.25 |
| Debt / FCF | n/a |
| Interest Coverage | 7.96 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 9.73% |
| Return on Capital Employed (ROCE) | 12.34% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 5.06M |
| Profits Per Employee | 660,715 |
| Employee Count | 1,915 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:SYMBIOTEC has paid 301.03 million in taxes.
| Income Tax | 301.03M |
| Effective Tax Rate | 19.22% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1,215.38 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 68.08 |
| Average Volume (20 Days) | 917,982 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:SYMBIOTEC had revenue of INR 9.69 billion and earned 1.27 billion in profits. Earnings per share was 20.63.
| Revenue | 9.69B |
| Gross Profit | 6.16B |
| Operating Income | 1.93B |
| Pretax Income | 1.57B |
| Net Income | 1.27B |
| EBITDA | 2.68B |
| EBIT | 1.93B |
| Earnings Per Share (EPS) | 20.63 |
Full Income Statement Balance Sheet
The company has 217.66 million in cash and 3.36 billion in debt, with a net cash position of -3.14 billion or -48.89 per share.
| Cash & Cash Equivalents | 217.66M |
| Total Debt | 3.36B |
| Net Cash | -3.14B |
| Net Cash Per Share | -48.89 |
| Equity (Book Value) | 13.61B |
| Book Value Per Share | 215.75 |
| Working Capital | 1.72B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 948.61 million and capital expenditures -2.29 billion, giving a free cash flow of -1.34 billion.
| Operating Cash Flow | 948.61M |
| Capital Expenditures | -2.29B |
| Depreciation & Amortization | 745.15M |
| Net Borrowing | -1.83B |
| Free Cash Flow | -1.34B |
| FCF Per Share | -20.89 |
Full Cash Flow Statement Margins
Gross margin is 63.65%, with operating and profit margins of 19.93% and 13.06%.
| Gross Margin | 63.65% |
| Operating Margin | 19.93% |
| Pretax Margin | 16.17% |
| Profit Margin | 13.06% |
| EBITDA Margin | 27.62% |
| EBIT Margin | 19.93% |
| FCF Margin | n/a |
Dividends & Yields
NSE:SYMBIOTEC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -9.97% |
| Shareholder Yield | -9.97% |
| Earnings Yield | 1.32% |
| FCF Yield | -1.33% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for NSE:SYMBIOTEC is 1,654.00, which is 5.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1,654.00 |
| Price Target Difference | 5.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 27.63% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |